IL17A and colorectal cancer: TTI-101 treatment reduced the number of IL-17-positive cells infiltrating the colon and modulated levels of DSS-induced mRNA transcripts involved in inflammation, apoptosis, colorectal cancer metastasis, and large intestinal neoplasms.